I-View
Hologic, Inc. · Decision date Sep 2, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision for K254090 on September 2, 2026, covering Hologic, Inc.'s I-View® contrast-enhanced digital mammography software, version 3.0, a Class II full-field digital mammography system under 21 CFR 892.1715 with product code MUE. The submission was dated December 16, 2025 and received December 19, 2025. The device is optional CEDM software for the Envision Mammography Platform (P080003/S009), acquiring low- and high-energy 2D images during a single compression.
The comparison document names I-View® CEDM software cleared as K123873 (January 29, 2013) as the predicate, and states the only indication difference is the imaging platform used to obtain images. SE denotes 510(k) clearance, not PMA approval. The source does not include the clearance letter's full text, performance data, or any statement on clinical accuracy, so those remain unknown.
The summary lists IEC 62304:2015 and ISO 14971:2019 as standards and describes use as an adjunct following mammography and/or ultrasound to localize a known or suspected lesion, with MQSA-qualified interpreting physicians and radiologists as end users.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Radiology
- Decision date
- Sep 2, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K254090
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Hologic, Inc.
- Product code
- MUE
- Decision code
- SESE
- Decision date
- Sep 2, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Full Field Digital, System, X-Ray, Mammographic.
- Applicant
- Hologic, Inc.
- Product code
- MUE
- FDA device class
- 2
FDA decision timeline
K254090 received
Application receipt date recorded by FDA.
K254090 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Hologic, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Newark, DE
Sources and methodology
- Original FDA record: K254090
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records